The Society for Neuro-Oncology (SNO) is conducting a survey to assess the impact of the proposed discontinuation of the patient assistance program for temozolomide, as well as the discontinuation of certain pill dosages by the manufacturer.
SNO is seeking to better understand the impact these changes will have on patients and the neuro-oncology community in general. SNO will share the information from the survey with lawmakers on Capitol Hill, as well as with other relevant stakeholders in the neuro-oncology community.
It is anticipated that the survey will take less than 5 minutes to complete. On behalf of the SNO Public Policy Committee, your participation and input are appreciated.